Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06873789 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumors and Solid Tumors, sponsored by Incyte Corporation.

Active
Registry status
Phase 1
Development phase
9
Enrollment target
9
Study locations

NCT06873789 is a Phase 1 study of Advanced Solid Tumors and Solid Tumors that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 9 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06873789, a Phase 1 study of Advanced Solid Tumors and Solid Tumors, is active but no longer recruiting, sponsored by Incyte Corporation.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
9 participants
Enrollment target
9
Study locations

Study Summary

This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.

Conditions Studied

Advanced Solid Tumors Solid Tumors Metastatic Solid Tumors

Interventions

  • DRUG Retifanlimab
  • DRUG INCB177054

Study Locations (9)

California

  • The Angeles Clinic and Research Institute - Los Angeles
  • Valkyrie Clinical Trials - Panorama City

Florida

  • University of Florida Health Shands Hospital - Gainesville

Michigan

  • Cancer and Hematology Centers of Western Michigan-Start Midwest - Grand Rapids

New Jersey

  • Hackensack University Medical Center - Hackensack

North Carolina

  • Carolina Bio Oncology - Huntersville

Oregon

  • Providence Cancer Institute Franz Clinic - Portland

Pennsylvania

  • Upmc Cancercenter - Pittsburgh

Texas

  • South Texas Accelerated Research Therapeutics - San Antonio

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2025-06-30
Est. Completion 2028-10-30
Phase Phase 1

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06873789

The ClinicalTrials.gov registry entry for NCT06873789 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (95% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Retifanlimab is the first listed.

NCT06873789 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT06873789 about?

NCT06873789 is a clinical study titled "A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors". This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.

What is the current status of trial NCT06873789?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2025-06-30. Estimated completion is 2028-10-30.

What conditions does trial NCT06873789 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Solid Tumors, Metastatic Solid Tumors.

What interventions are being tested in trial NCT06873789?

The interventions under investigation include: Retifanlimab (DRUG), INCB177054 (DRUG).

Who is sponsoring clinical trial NCT06873789?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06873789 being conducted?

This trial has 9 study locations across California, Florida, Michigan, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.